News about Industrial talks

Jubilant Pharmova Appoints Daniel J. O'Connor as CEO of Jubilant Therapeutics

Jubilant Pharmova has announced the appointment of Daniel J. O’Connor as CEO of its proprietary novel drugs business, Jubilant Therapeutics Inc.

Industrial talks | 02/12/2025 | By Dineshwori |  301

Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions

Tsingke Biotech showcased its accelerated protein and antibody production platform at PEGS Europe 2025, announcing capabilities to generate proteins in as little as three days and antibodies within seven—offering a boost to biopharma developers seeking faster drug discovery timelines.

Industrial talks | 20/11/2025 | By Dineshwori |  258

Merus, Halozyme Partner to Develop Subcutaneous Petosemtamab

Under the agreement, Merus will pay Halozyme upfront and milestone-based payments, with Halozyme also eligible for low- to mid-single-digit royalties on future ENHANZE-enabled petosemtamab sales.

Industrial talks | 19/11/2025 | By Dineshwori |  319

Health Minister Marks AMRIT Pharmacy's 10th Anniversary, Announces Nationwide Expansion

AMRIT pharmacies offer medicines at discounts of around 50 percent, benefiting more than 6.85 crore patients to date. Medicines valued at over INR 17,000 crore have been dispensed through the network, resulting in cumulative patient savings of approximately INR 8,400 crore, according to the data shared.

Industrial talks | 17/11/2025 | By Dineshwori |  337

Pfizer Completes Acquisition of Metsera

Pfizer has finalised its acquisition of Metsera, adding a portfolio of differentiated, clinical-stage obesity therapies with the potential to redefine future treatment standards. The deal strengthens and reshapes Pfizer’s internal medicine portfolio, positioning the company to compete more aggressively in therapeutic areas, globally.

Industrial talks | 14/11/2025 | By Dineshwori |  254

Biocon Clarifies Media Reports on Possible Biocon Biologics Merger

Biocon has issued a clarification regarding recent media reports suggesting that the company is considering a potential merger of its unlisted subsidiary, Biocon Biologics Ltd. (BBL), along with IPO and share swap options.

Industrial talks | 14/11/2025 | By Dineshwori |  440

US FDA Appoints Richard Pazdur as Director of CDER

Pazdur is a 26-year veteran of the FDA and the Founding Director of its Oncology Center of Excellence (CoE). A regulatory innovator, he developed an integrated approach for cross-centre coordination of oncology product review to expedite the development of novel cancer therapies.

Industrial talks | 13/11/2025 | By Dineshwori |  424

Biocon Posts Robust Q2FY26 Results as Biosimilars and Generics Drive Double-Digit Growth

Biocon reported a robust financial performance for the second quarter of FY26, with total revenue rising 21 percent year-on-year (YoY) to INR 4,389 crore, compared to INR 3,623 crore in Q2 FY25.

Industrial talks | 12/11/2025 | By Dineshwori |  505

Novo Nordisk Confirms No Further Proposal Increase for Metsera Acquisition

Novo Nordisk has confirmed that it will not increase its offer to acquire Metsera, ending speculation of a potential bidding escalation.

Industrial talks | 10/11/2025 | By Dineshwori |  289

Senores Pharma Subsidiary Acquires Stake in Zoraya Pharmaceuticals

The acquisition of stakes in Zoraya Pharmaceuticals marks Senores Pharma’s strategic expansion in the US market through its wholly owned subsidiary.

Industrial talks | 06/11/2025 | By Dineshwori |  660